Lessons from the failure of the adenovector HIV vaccine.
The much-publicised halting of the joint Merck/HIV Vaccine Trials Network phase IIB candidate HIV-1 vaccine trial in 2007 has led to an unprecedented degree of discussion and introspection amongst the HIV research community. In this commentary, we will summarise the lessons learned from the trial an...
Main Authors: | Blais, M, Rowland-Jones, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
by: Machteld M. Tiemessen, et al.
Published: (2022-08-01) -
Protective immunity against HIV infection: lessons from HIV-2 infection.
by: Rowland-Jones, S
Published: (2006) -
High-capacity adenovector delivery of forced CRISPR-Cas9 heterodimers fosters precise chromosomal deletions in human cells
by: Francesca Tasca, et al.
Published: (2023-03-01) -
HIV: vaccines out of Africa.
by: Rowland-Jones, S
Published: (2001) -
Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.
by: Leligdowicz, A, et al.
Published: (2008)